417 related articles for article (PubMed ID: 2416968)
1. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
Matsuda T
Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
[No Abstract] [Full Text] [Related]
2. [Recent progress in fibrinolytic mechanism].
Yasukouchi T
Rinsho Byori; 1986 Mar; 34(3):235-46. PubMed ID: 3086600
[No Abstract] [Full Text] [Related]
3. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
Veremeenko KN; Kizim AI
Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
[TBL] [Abstract][Full Text] [Related]
4. [Blood coagulation mechanism from the viewpoint of molecular biochemistry].
Hashimoto S; Asai K
Rinsho Byori; 1985 Sep; 33(9):957-9. PubMed ID: 2934563
[No Abstract] [Full Text] [Related]
5. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
[TBL] [Abstract][Full Text] [Related]
6. [Enzymatic fibrinolytic agents].
Jamet M; Granthil C; Levy G
Ann Anesthesiol Fr; 1978; 19(8):693-6. PubMed ID: 31112
[TBL] [Abstract][Full Text] [Related]
7. [Molecular mechanisms of thrombolytic therapy].
Lijnen HR; Collen D
Haemostasis; 1986; 16 Suppl 4():3-15. PubMed ID: 2945768
[No Abstract] [Full Text] [Related]
8. [Natural inhibitors of fibrinolysis].
Juhan-Vague I; Aillaud MF; Serradimigni A
Haemostasis; 1986; 16 Suppl 4():16-20. PubMed ID: 3095197
[No Abstract] [Full Text] [Related]
9. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
10. Fibrin-specific fibrinolysis.
Collen D; Lijnen HR
Ann N Y Acad Sci; 1992 Dec; 667():259-71. PubMed ID: 1285022
[No Abstract] [Full Text] [Related]
11. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
12. Extrinsic plasminogen activator: a new principle in fibrinolysis.
Lijnen HR
Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic agents and their effects on the haemostatic system.
Kluft C
Klin Wochenschr; 1988; 66 Suppl 12():50-4. PubMed ID: 2964542
[TBL] [Abstract][Full Text] [Related]
14. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
15. [Streptokinase or urokinase: the elements of choice].
Pâques EP
Haemostasis; 1986; 16 Suppl 4():21-5. PubMed ID: 2429902
[No Abstract] [Full Text] [Related]
16. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
[No Abstract] [Full Text] [Related]
17. Thrombolytic therapy in the eighties.
Verstraete M; Collen D
Blood; 1986 Jun; 67(6):1529-41. PubMed ID: 2423156
[No Abstract] [Full Text] [Related]
18. Plasminogen activation system of the platelets.
Park S
Rinsho Byori; 1992 Mar; Suppl 92():131-43. PubMed ID: 1583771
[No Abstract] [Full Text] [Related]
19. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
20. Natural inhibitors of fibrinolysis.
Juhan-Vague I; Aillaud MF; Serradimigni A
Haemostasis; 1986; 16 Suppl 3():16-20. PubMed ID: 3095194
[No Abstract] [Full Text] [Related]
[Next] [New Search]
